Sean D McAllister
Overview
Explore the profile of Sean D McAllister including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
926
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Murase R, Kawamura R, Singer E, Pakdel A, Sarma P, Judkins J, et al.
Br J Pharmacol
. 2014 Jun;
171(19):4464-77.
PMID: 24910342
Background And Purpose: The psychoactive cannabinoid Δ(9) -tetrahydrocannabinol (THC) and the non-psychoactive cannabinoid cannabidiol (CBD) can both reduce cancer progression, each through distinct anti-tumour pathways. Our goal was to discover...
12.
Ward S, McAllister S, Kawamura R, Murase R, Neelakantan H, Walker E
Br J Pharmacol
. 2013 Oct;
171(3):636-45.
PMID: 24117398
Background And Purpose: Paclitaxel (PAC) is associated with chemotherapy-induced neuropathic pain (CIPN) that can lead to the cessation of treatment in cancer patients even in the absence of alternate therapies....
13.
Sumida T, Murase R, Onishi-Ishikawa A, McAllister S, Hamakawa H, Desprez P
BMC Cancer
. 2013 Mar;
13:141.
PMID: 23517130
Background: Salivary gland cancer (SGC) is one of the common malignancies of the head and neck area. It develops in the minor and major salivary glands and sometimes metastasizes to...
14.
Soroceanu L, Murase R, Limbad C, Singer E, Allison J, Adrados I, et al.
Cancer Res
. 2012 Dec;
73(5):1559-69.
PMID: 23243024
Glioblastoma is the most common form of primary adult brain tumors. A majority of glioblastomas grow invasively into distant brain tissue, leading to tumor recurrence, which is ultimately incurable. It...
15.
Novel therapeutic strategies for malignant salivary gland tumors: lessons learned from breast cancer
Murase R, Sumida T, Ishikawa A, Murase R, McAllister S, Hamakawa H, et al.
Int J Otolaryngol
. 2011 Dec;
2011:187623.
PMID: 22164169
Malignant salivary gland tumors (MSGTs) account for 2-6% of all head and neck cancers. Despite the rarity, MSGTs have been of great interest due to a wide variety of pathological...
16.
McAllister S, Murase R, Christian R, Lau D, Zielinski A, Allison J, et al.
Breast Cancer Res Treat
. 2010 Sep;
129(1):37-47.
PMID: 20859676
Invasion and metastasis of aggressive breast cancer cells are the final and fatal steps during cancer progression. Clinically, there are still limited therapeutic interventions for aggressive and metastatic breast cancers...
17.
Marcu J, Christian R, Lau D, Zielinski A, Horowitz M, Lee J, et al.
Mol Cancer Ther
. 2010 Jan;
9(1):180-9.
PMID: 20053780
The cannabinoid 1 (CB(1)) and cannabinoid 2 (CB(2)) receptor agonist Delta(9)-tetrahydrocannabinol (THC) has been shown to be a broad-range inhibitor of cancer in culture and in vivo, and is currently...
18.
McAllister S, Christian R, Horowitz M, Garcia A, Desprez P
Mol Cancer Ther
. 2007 Nov;
6(11):2921-7.
PMID: 18025276
Invasion and metastasis of aggressive breast cancer cells is the final and fatal step during cancer progression, and is the least understood genetically. Clinically, there are still limited therapeutic interventions...
19.
McAllister S, Chan C, Taft R, Luu T, Abood M, Moore D, et al.
J Neurooncol
. 2005 Aug;
74(1):31-40.
PMID: 16078104
Normal tissue toxicity limits the efficacy of current treatment modalities for glioblastoma multiforme (GBM). We evaluated the influence of cannabinoids on cell proliferation, death, and morphology of human GBM cell...
20.
McAllister S, Hurst D, Barnett-Norris J, Lynch D, Reggio P, Abood M
J Biol Chem
. 2004 Aug;
279(46):48024-37.
PMID: 15326174
In this study, we tested the hypothesis that a CB(1) TMH3-4-5-6 aromatic microdomain, which includes F3.25(190), F3.36(201), W5.43(280), and W6.48(357), is centrally involved in CB(1) receptor activation, with the F3.36(201)/W6.48(357)...